# EMPAGLIFLOZIN; LINAGLIPTIN
> **ANDA212364** · Abbreviated New Drug Application (Generic) · Sponsor: ANNORA PHARMA · Approved 2021-03-30
## Drug
- **FDA Application Number:** ANDA212364
- **Application type:** Abbreviated New Drug Application (Generic)
- **Brand name:** EMPAGLIFLOZIN; LINAGLIPTIN
- **Generic name:** Empagliflozin
- **Active ingredients:** EMPAGLIFLOZIN; LINAGLIPTIN
- **Dosage form:** TABLET
- **Route:** ORAL
- **Marketing status:** None (Tentative Approval)
- **Sponsor:** ANNORA PHARMA
- **First approval:** 2021-03-30
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212364)
---
*AI Analytics · CC0 1.0*